Project Grant R21AI178424
Award Date
9/1/24
Completion Date
7/31/26
Dollars Obligated
$282K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Washington, USA
Similar Awards
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $219,122 to the University of Illinois to conduct research on Salmonella Typhimurium infection. The goal is to understand the mechanisms of gene regulation that control the bacteria's ability to infect and colonize host cells. The research focuses on characterizing a novel small RNA-mediated regulatory system that...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $127,302 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Regents of the University of Michigan. The grant, awarded on January 18, 2025, supports research to understand how the integrated stress response (ISR) in macrophages shapes the innate immune response and infection outcomes during Salmonella enterica serovar Typhi (STy) infection. The research aims to reveal the role of...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $204,347 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to the University of Vermont & State Agricultural College to study the intracellular colonization strategies of Salmonella enterica serovar Typhimurium within human intestinal epithelial cells and macrophages. The research aims to characterize bacterial and host transcripts during Salmonella infection, distinguish between cytosolic and...
This Project Grant award, ID R01AI175440, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The $728,695 grant, awarded on Sep 1, 2024, will fund research at the University of Arkansas for Medical Sciences (UAMS) to investigate mechanisms of antibiotic resistance and heteroresistance to the novel cephalosporin antibiotic cefiderocol in carbapenem-resistant Gram-negative pathogens. The...
This federal Project Grant award of $254,478 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to identify mechanisms of resistance to pathogen-specific antibacterial antisense compounds and develop strategies to overcome them. The award recipient, The University of Texas Southwestern Medical Center, will investigate resistance to these novel antibacterial compounds called...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $212,169 to The Johns Hopkins University to advance mentorship and research capabilities related to combating antimicrobial resistant (AMR) infections. The award will enable the principal investigator to enhance their expertise in constructing site-directed mutants of key β-lactamase enzymes and integrating...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $1,144,714 to the University of Illinois to conduct research aimed at discovering novel antibiotics for gram-negative pathogens. The primary goals are to identify physicochemical traits that allow antibiotics to evade efflux pumps in E. coli, P. aeruginosa, and A. baumannii, and then apply this knowledge to develop at...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $569,210 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Colorado Boulder. The grant will fund research to structurally and functionally characterize three key proteins responsible for resistance to cationic antimicrobial peptides (CAMPs) and the antibiotic colistin in gram-negative bacteria. The research aims to close knowledge gaps around the biochemical...
This $408,375 Project Grant, awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to elucidate phage resistance mechanisms in Mycobacterium abscessus (MAB) and assess how these can be leveraged to enhance the efficacy of antibiotic therapy. The overarching goal is to deepen the fundamental understanding of phage-mycobacteria interactions and apply this knowledge to develop...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $474,363.00 to Rowan University to develop novel antimicrobial peptides inspired by the clinically approved compound daptomycin. The goal is to create new peptide molecules that mimic daptomycin's key mechanisms of action, such as calcium binding and lipid membrane disruption, while improving resistance to...